ArticleCureus2026
A Rare Dual Complication of First-Line Anti-tubercular Therapy: A Case Report of Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome and Ethambutol-Induced Optic Neuropathy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is an extremely rare and serious systemic drug reaction, often posing significant diagnostic challenge to clinicians. Ethambutol-induced optic neuropathy (EON) is a well-recognised but often insidious complication of first-line anti-tubercular therapy (ATT), typically manifesting as reduced visual acuity, and visual field defects. We report the case of a 78-year-old woman with confirmed diagnosis of pulmonary tuberculosis, who simultaneously developed probable DRESS syndrome, secondary to rifampicin and EON shortly after initiation of the standard first-line ATT regimen (isoniazid, rifampicin, pyrazinamide, and ethambutol). Early diagnosis and prompt withdrawal of the offending drugs helped her to achieve complete recovery with no complications. This case highlights the importance of a high index of suspicion and early recognition of drug-induced adverse reactions in patients on multi-drug ATT regimens, as timely diagnosis and management can help in preventing serious complications like permanent vision loss, and also death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.